JP2006519216A - Ｍｍｐ阻害活性を有する画像診断剤 - Google Patents

Ｍｍｐ阻害活性を有する画像診断剤 Download PDF

Info

Publication number
JP2006519216A
JP2006519216A JP2006502261A JP2006502261A JP2006519216A JP 2006519216 A JP2006519216 A JP 2006519216A JP 2006502261 A JP2006502261 A JP 2006502261A JP 2006502261 A JP2006502261 A JP 2006502261A JP 2006519216 A JP2006519216 A JP 2006519216A
Authority
JP
Japan
Prior art keywords
diagnostic imaging
imaging agent
compound
formula
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006502261A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006519216A5 (enExample
Inventor
ストーレイ，アンソニー
デイビス，ジュリー
リケッツ，サリー−アン
メンディザバル，マリヴィ
カスバートソン，アラン
アルクヴェ，ヨーゼフ
ヘイウッド，カースティ
ウィルソン，イアン
ウィン，ダンカン
シェイファース、ミハエル
レフカウ、ボードー
ヴァーグナー，シュテファン
ブレイホルツ，ハンス−ヨルグ
コプカ，クラウス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
Original Assignee
GE Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0302891A external-priority patent/GB0302891D0/en
Priority claimed from GB0307524A external-priority patent/GB0307524D0/en
Application filed by GE Healthcare Ltd filed Critical GE Healthcare Ltd
Publication of JP2006519216A publication Critical patent/JP2006519216A/ja
Publication of JP2006519216A5 publication Critical patent/JP2006519216A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nuclear Medicine (AREA)
JP2006502261A 2003-02-10 2004-02-10 Ｍｍｐ阻害活性を有する画像診断剤 Pending JP2006519216A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0302891A GB0302891D0 (en) 2003-02-10 2003-02-10 Diagnostic imaging agents for cardiovascular disease
GB0307524A GB0307524D0 (en) 2003-04-01 2003-04-01 Diagnostic imaging agents with MMP inhibitory activity
PCT/GB2004/000524 WO2004069365A1 (en) 2003-02-10 2004-02-10 Diagnostic imaging agents with mmp inhibitory activity

Publications (2)

Publication Number Publication Date
JP2006519216A true JP2006519216A (ja) 2006-08-24
JP2006519216A5 JP2006519216A5 (enExample) 2007-03-29

Family

ID=32852413

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006502261A Pending JP2006519216A (ja) 2003-02-10 2004-02-10 Ｍｍｐ阻害活性を有する画像診断剤

Country Status (8)

Country Link
US (1) US8231858B2 (enExample)
EP (1) EP1592458A1 (enExample)
JP (1) JP2006519216A (enExample)
AU (1) AU2004210208B2 (enExample)
CA (1) CA2514885A1 (enExample)
NO (1) NO20053776L (enExample)
RU (1) RU2005123801A (enExample)
WO (1) WO2004069365A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011528688A (ja) * 2008-07-22 2011-11-24 ブラッコ・イメージング・ソシエタ・ペル・アチオニ メタロプロテアーゼの選択的診断剤

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0326546D0 (en) * 2003-11-14 2003-12-17 Amersham Plc Inhibitor imaging agents
GB0421308D0 (en) * 2004-09-24 2004-10-27 Amersham Plc Enzyme inhibitor imaging agents
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
CA2625196C (fr) 2005-10-07 2016-04-05 Guerbet Composes comprenant une partie de reconnaissance d'une cible biologique, couplee a une partie de signal capable de complexer le gallium
ES2641727T3 (es) * 2006-10-06 2017-11-13 Mallinckrodt Nuclear Medicine Llc Sistema de elución de radioisótopos de autoalineación
EP2149568A1 (en) 2008-07-22 2010-02-03 Bracco Imaging S.p.A Aryl-sulphonamidic dimers as metalloproteases inhibitors
US9153350B2 (en) 2011-01-19 2015-10-06 Mallinckrodt Llc Protective shroud for nuclear pharmacy generators
US8809804B2 (en) * 2011-01-19 2014-08-19 Mallinckrodt Llc Holder and tool for radioisotope elution system
US8866104B2 (en) 2011-01-19 2014-10-21 Mallinckrodt Llc Radioisotope elution system
WO2013010573A1 (en) * 2011-07-18 2013-01-24 Universitaet Muenster Compounds with matrix-metalloproteinase inhibitory activity
US9023318B2 (en) * 2011-06-08 2015-05-05 Siemens Medical Solutions Usa, Inc. Compounds with matrix-metalloproteinase inhibitory activity and imaging agents thereof
EP2775906B1 (en) * 2011-11-11 2019-07-03 Yale University Evaluation of presence of and vulnerability to atrial fibrillation and other indications using matrix metalloproteinase-based imaging
EP2644601A1 (en) * 2012-03-28 2013-10-02 Westfälische Wilhelms-Universität Münster Compounds with matrix-metalloproteinase inhibitory activity and imaging agents thereof
GB202012671D0 (en) * 2020-08-13 2020-09-30 Nrf Ithemba Labs Theranostic Compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11505502A (ja) * 1994-06-24 1999-05-21 ノバルティス アクチェンゲゼルシャフト マトリックスメタロプロテイナーゼ阻害剤としてのアリールスルホンアミド置換ヒドロキサム酸類
WO2001060416A2 (en) * 2000-02-15 2001-08-23 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors as targeting components in diagnostic agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4427646A (en) * 1981-04-02 1984-01-24 Research Corporation Use of radiolabeled peptide derived from crosslinked fibrin to locate thrombi in vivo
TW453995B (en) * 1995-12-15 2001-09-11 Novartis Ag Certain alpha-substituted arylsulfonamido acetohydroxamic acids
AU7294098A (en) * 1997-05-09 1998-11-27 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US6989139B2 (en) * 2000-02-15 2006-01-24 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
EP1309579B1 (en) * 2000-05-30 2005-10-12 Board Of Governors Of Wayne State University Inhibitors of matrix metalloproteinases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11505502A (ja) * 1994-06-24 1999-05-21 ノバルティス アクチェンゲゼルシャフト マトリックスメタロプロテイナーゼ阻害剤としてのアリールスルホンアミド置換ヒドロキサム酸類
WO2001060416A2 (en) * 2000-02-15 2001-08-23 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors as targeting components in diagnostic agents

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011528688A (ja) * 2008-07-22 2011-11-24 ブラッコ・イメージング・ソシエタ・ペル・アチオニ メタロプロテアーゼの選択的診断剤
US9480758B2 (en) 2008-07-22 2016-11-01 Bracco Imaging S.P.A. Diagnostic agents selective against metalloproteases

Also Published As

Publication number Publication date
AU2004210208A1 (en) 2004-08-19
AU2004210208B2 (en) 2007-06-07
US20070071670A1 (en) 2007-03-29
NO20053776L (no) 2005-09-30
RU2005123801A (ru) 2006-03-27
US8231858B2 (en) 2012-07-31
WO2004069365A1 (en) 2004-08-19
WO2004069365A8 (en) 2004-09-30
EP1592458A1 (en) 2005-11-09
CA2514885A1 (en) 2004-08-19
NO20053776D0 (no) 2005-08-09

Similar Documents

Publication Publication Date Title
JP2006519216A (ja) Ｍｍｐ阻害活性を有する画像診断剤
JP2019011368A (ja) 前立腺特異的膜抗原（ｐｓｍａ）の標識インヒビター、前立腺癌の治療のための画像化剤および薬剤としてのその使用
JP5043438B2 (ja) 阻害剤造影剤
JP7584426B2 (ja) 改善された組織特異性を有する前立腺特異的膜抗原（ｐｓｍａ）リガンド
US20030007927A1 (en) Radiopharmaceuticals for imaging infection and inflammation
JP7213493B2 (ja) ニューロテンシン受容体関連病態の診断、治療及び予防
JP6087386B2 (ja) 造影剤としてのｎ−アルコキシアミド抱合体
KR20080022588A (ko) 영상화제로서의 히드라지드 컨쥬게이트
JP2008514580A (ja) 酵素阻害剤造影剤
US6770259B2 (en) Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation
JP7566247B2 (ja) アミラーゼ切断可能なリンカーを含む前立腺特異的膜抗原（ｐｓｍａ）リガンド
JP4723378B2 (ja) 石灰化組織親和性化合物
NZ335539A (en) Radiopharmaceuticals for imaging infection and useful for inflammation
JP2006505550A (ja) バルビツール酸誘導体を含む進歩した造影剤
US12486294B2 (en) Radioisotope labeled compound for imaging or treatment of prostate cancer
EP2520573A1 (en) Compounds with matrix-metalloproteinase inhibitory activity
WO2025088147A1 (en) Theranostic psma-targeting ligands for the diagnosis and treatment of psma-expressing cancers and their solid phase synthesis
HK1255215A1 (zh) 用於成像和治疗的尿素基前列腺特异性膜抗原(psma)抑制剂
HK1255215B (en) Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100525

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101130